Predict your next investment

Venture Capital
FINANCE | Investment Firms & Funds
abingworth.com

See what CB Insights has to offer

Investments

318

Portfolio Exits

109

Funds

18

Service Providers

3

About Abingworth

Abingworth is an international investment group focused exclusively on the life sciences and healthcare sectors. It was founded in 1973 and is based in London, England.

Abingworth Headquarter Location

38 Jermyn Street

London, England, SW1Y 6DN,

United Kingdom

+ 44 (0)20 7534 1500

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Abingworth

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Abingworth in 2 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

382 items

C

CB Insights Healthcare Smart Money Investors - 2020

25 items

Track the world's top-performing VC investors in healthcare. Firms are presented in alphabetical order.

Abingworth Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Abingworth Rank

Research containing Abingworth

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Abingworth in 4 CB Insights research briefs, most recently on Feb 16, 2021.

Latest Abingworth News

Carlyle Completes Acquisition of Abingworth and Announces Go-forward Leadership Team; Acquisition Expands Global Healthcare Fran...

Aug 3, 2022

10h agoVenture CapitalcarlyleViews: 7 Not a member yet? Free Membership for Qualified Investors and Industry Participants Easily Customize Content to Match Your Investment Preferences Breaking News 24/7/365 Alternative Investment Listings & LeaderBoards Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets,Presentations, Investment Mandates, Video PitchBooks & More! Company Directory AUM Accelerator Program (designed for investment managers) Over 450K+ Industry Headlines, Posts and Updates ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY.CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN.PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS.THIS IS NOT A SOLICITATION FOR INVESTMENT.THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY.IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES.ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM.PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT. ALPHAMAVEN

Abingworth Investments

318 Investments

Abingworth has made 318 investments. Their latest investment was in VenatoRx Pharmaceuticals as part of their Series C on April 4, 2022.

CBI Logo

Abingworth Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/4/2022

Series C

VenatoRx Pharmaceuticals

$34M

No

3

9/30/2021

Seed VC

Brave Bio

$5.25M

Yes

1

9/16/2021

Series A

Anjarium Biosciences

$61M

Yes

14

9/8/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

7/15/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/4/2022

9/30/2021

9/16/2021

9/8/2021

7/15/2021

Round

Series C

Seed VC

Series A

Series A

Series B

Company

VenatoRx Pharmaceuticals

Brave Bio

Anjarium Biosciences

Subscribe to see more

Subscribe to see more

Amount

$34M

$5.25M

$61M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

1

14

10

10

Abingworth Portfolio Exits

109 Portfolio Exits

Abingworth has 109 portfolio exits. Their latest portfolio exit was HilleVax on April 29, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/29/2022

IPO

$99M

Public

5

1/10/2022

Acquired

$99M

11

10/27/2021

Acquired

$99M

4

9/24/2021

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

5/27/2021

Acq - Pending

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/29/2022

1/10/2022

10/27/2021

9/24/2021

5/27/2021

Exit

IPO

Acquired

Acquired

Reverse Merger

Acq - Pending

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

5

11

4

10

10

Abingworth Acquisitions

1 Acquisition

Abingworth acquired 1 company. Their latest acquisition was Stanmore Implants on February 25, 2008.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

2/25/2008

Debt

$99M

$13.95M

Acq - Fin

1

Date

2/25/2008

Investment Stage

Debt

Companies

Valuation

$99M

Total Funding

$13.95M

Note

Acq - Fin

Sources

1

Abingworth Fund History

18 Fund Histories

Abingworth has 18 funds, including Abingworth Clinical Co-Development Fund 2.

Closing Date

Fund

Fund Type

Status

Amount

Sources

5/10/2021

Abingworth Clinical Co-Development Fund 2

$582M

2

5/10/2021

Abingworth Clinical Co-Development Fund 3

$582M

1

2/3/2021

Abingworth Bioventures 8

$465M

3

7/9/2018

Abingworth BioVentures VII

$99M

10

5/30/2018

Abingworth Bioventures VII

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

5/10/2021

5/10/2021

2/3/2021

7/9/2018

5/30/2018

Fund

Abingworth Clinical Co-Development Fund 2

Abingworth Clinical Co-Development Fund 3

Abingworth Bioventures 8

Abingworth BioVentures VII

Abingworth Bioventures VII

Fund Type

Subscribe to see more

Status

Subscribe to see more

Amount

$582M

$582M

$465M

$99M

$99M

Sources

2

1

3

10

10

Abingworth Service Providers

3 Service Providers

Abingworth has 3 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

General Counsel

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Subscribe to see more

Associated Rounds

Provider Type

Counsel

Subscribe to see more

Subscribe to see more

Service Type

General Counsel

Subscribe to see more

Subscribe to see more

Partnership data by VentureSource

Abingworth Team

7 Team Members

Abingworth has 7 team members, including current Chief Financial Officer, Neil Cooper.

Name

Work History

Title

Status

Neil Cooper

Baird, Advent Life Sciences, and KPMG

Chief Financial Officer

Current

Stephen Bunting

Managing Partner

Current

Kurt von Emster

MPM Capital, and Franklin Resources

Managing Partner

Current

Tim Haines

Managing Partner

Current

Genghis Lloyd Harris

Credit Suisse First Boston

Managing Partner

Current

Name

Neil Cooper

Stephen Bunting

Kurt von Emster

Tim Haines

Genghis Lloyd Harris

Work History

Baird, Advent Life Sciences, and KPMG

MPM Capital, and Franklin Resources

Credit Suisse First Boston

Title

Chief Financial Officer

Managing Partner

Managing Partner

Managing Partner

Managing Partner

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.